Drug Profile
Modakafusp alfa - Takeda/Teva Pharmaceutical Industries
Alternative Names: TAK-573; TEV-48573Latest Information Update: 25 Dec 2023
Price :
$50
*
At a glance
- Originator Teva Pharmaceutical Industries
- Developer Takeda
- Class Antibodies; Antineoplastics; Immunoglobulin fragments; Immunotherapies; Interferons; Recombinant fusion proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma; Multiple myeloma; Solid tumours
Most Recent Events
- 04 Nov 2023 Takeda completes a phase I/II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy, Recurrent, Second-line therapy or greater) in Australia and USA (IV) (NCT04157517)
- 04 Nov 2023 Takeda completes a phase I/II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Recurrent, Second-line therapy or greater) in Australia and USA (IV) (NCT04157517)
- 30 Jun 2023 Discontinued - Phase-I for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Austria (IV)